Abstract
Pharmacoepidemiology studies the utilization patterns of medicines—also known as drug utilization research—which is an important component of pharmacy practice research. Pharmacoepidemiology also studies the relationship between medicines or other medical treatments and outcomes in large populations under nonexperimental situations. Providing an introduction to pharmacoepidemiology, this chapter describes frequently used metrics to understand drug utilization and medication adherence. This chapter also covers the key concepts involved in studying the association between medical or surgical treatments and outcomes. These concepts include forming a research question, selecting sources of data, defining the study population, and defining drug exposures, covariates, and outcomes. The chapter also discusses a range of study designs used in pharmacoepidemiologic research, including, but not limited to, cohort studies, case-control studies, within-subject studies, cross-sectional studies, ecological studies, and quasi-experimental designs. Finally, the chapter draws on key challenges such as confounding bias as well as commonly used analytical techniques to overcome these challenges.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adams AS, Zhang F, LeCates RF, et al. Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees. Arch Intern Med. 2009;169(8):750–6. https://doi.org/10.1001/archinternmed.2009.39.
Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565–74. https://doi.org/10.1002/pds.1230.
Arbogast PG, Ray WA. Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders. Am J Epidemiol. 2011;174(5):613–20. https://doi.org/10.1093/aje/kwr143.
Austin PC, Mamdani MM, Juurlink DN, Hux JE. Testing multiple statistical hypotheses resulted in spurious associations: a study of astrological signs and health. J Clin Epidemiol. 2006;59(9):964–9. https://doi.org/10.1016/j.jclinepi.2006.01.012.
Avorn J. The role of pharmacoepidemiology and pharmacoeconomics in promoting access and stimulating innovation. Pharmacoeconomics. 2004;22(2):81–6. https://doi.org/10.2165/00019053-200422002-00009.
Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. BMJ. 1993;307(6908):846–8.
Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878–86.
Berkson J. Limitations of the application of fourfold table analysis to hospital data. Biometrics. 1946;2(3):47–53.
Bertoldi AD, Barros AJ, Wagner A, Ross-Degnan D, Hallal PC. A descriptive review of the methodologies used in household surveys on medicine utilization. BMC Health Serv Res. 2008;8(1):222. https://doi.org/10.1186/1472-6963-8-222.
Bonamici S. Text—H.R.34—114th congress (2015–2016): 21st century cures act. https://www.congress.gov/bill/114th-congress/house-bill/34/text. Published 13 Dec 2016. Accessed 15 Oct 2019.
Breslow N. Design and analysis of case-control studies. Annu Rev Public Health. 1982;3(1):29–54. https://doi.org/10.1146/annurev.pu.03.050182.000333.
Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149–56. https://doi.org/10.1093/aje/kwj149.
Brookhart MA, Wang P, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006;17(3):268–75. https://doi.org/10.1097/01.ede.0000193606.58671.c5.
Brown J, Holmes J, Shah K, Hall K, Lazarus R, Platt R. Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Med Care. 2010;48(6):S45. https://doi.org/10.1097/MLR.0b013e3181d9919f.
Brown J, Kahn M, Toh S. Data quality assessment for comparative effectiveness research in distributed data networks. Med Care. 2013;51:S22. https://doi.org/10.1097/MLR.0b013e31829b1e2c.
Brunelli SM, Gagne JJ, Huybrechts KF, et al. Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates. Pharmacoepidemiol Drug Saf. 2013;22(5):542–50. https://doi.org/10.1002/pds.3434.
Choudhry NK, Shrank WH. Four-dollar generics—increased accessibility, impaired quality assurance. N Engl J Med. 2010;363(20):1885–7. https://doi.org/10.1056/NEJMp1006189.
Chung Y, Lu CY, Graham GG, Mant A, Day RO. Utilization of allopurinol in the Australian community. Intern Med J. 2008;38(6a):388–95. https://doi.org/10.1111/j.1445-5994.2008.01641.x.
Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887–92.
Cook NR, Cole SR, Hennekens CH. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the physicians’ health study. Am J Epidemiol. 2002;155(11):1045–53. https://doi.org/10.1093/aje/155.11.1045.
Dusetzina SB, Tyree S, Meyer A-M, Meyer A, Green L, Carpenter WR. Linking data for health services research: a framework and instructional guide. Rockville, MD: Agency for Healthcare Research and Quality (US); 2014. http://www.ncbi.nlm.nih.gov/books/NBK253313/. Accessed 15 Oct 2019.
Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol. 2005;5(1):5. https://doi.org/10.1186/1471-2288-5-5.
Etminan M. Pharmacoepidemiology II: The nested case-control study—a novel approach in pharmacoepidemiologic research. Pharmacotherapy. 2004;24(9):1105–9. https://doi.org/10.1592/phco.24.13.1105.38083.
Evans SJW. An agenda for UK clinical pharmacology: pharmacoepidemiology. Br J Clin Pharmacol. 2012;73(6):973–8. https://doi.org/10.1111/j.1365-2125.2012.04248.x.
Farrington CP. Re: “Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design”. Am J Epidemiol. 2004;159(7):717–8. https://doi.org/10.1093/aje/kwh093.
Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet. 1995;345(8949):567–9.
Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284–90. https://doi.org/10.1007/s11606-010-1253-9.
Glynn R, Knight E, Levin R, Avorn J. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology. 2001;12(6):682–9.
Goldacre M. The role of cohort studies in medical research. Pharmacoepidemiol Drug Saf. 2001;10(1):5–11. https://doi.org/10.1002/pds.562.
Gram LF, Hallas J, Andersen M. Pharmacovigilance based on prescription databases. Pharmacol Toxicol. 2000;86(s1):13–5. https://doi.org/10.1034/j.1600-0773.2000.d01-4.x.
Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2018;47(1):358. https://doi.org/10.1093/ije/dyx275.
Gurwitz JH, Sykora K, Mamdani M, et al. Reader’s guide to critical appraisal of cohort studies: 1. Role and design. BMJ. 2005;330(7496):895–7.
Hernán M, Brumback B, Robins J. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561–70.
Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–35. https://doi.org/10.1161/CIRCULATIONAHA.​108.768986.
Hubbard R, Farrington P, Smith C, Smeeth L, Tattersfield A. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol. 2003;158(1):77–84. https://doi.org/10.1093/aje/kwg114.
International Declaration on Human Genetic Data: UNESCO. http://portal.unesco.org/en/ev.php-URL_ID=17720&URL_DO=DO_TOPIC&URL_SECTION=201.html. Accessed 15 Oct 2019.
Introduction to Drug Utilization Research. https://apps.who.int/medicinedocs/en/d/Js4876e/. Accessed 15 Oct 15 2019.
Johnson ES, Bartman BA, Briesacher BA, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22(1):1–6. https://doi.org/10.1002/pds.3334.
Kelly E, Lu CY, Albertini S, Vitry A. Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison. J Clin Pharm Ther. 2015;40(1):76–82. https://doi.org/10.1111/jcpt.12227.
Kush RD, Helton E, Rockhold FW, Hardison CD. Electronic health records, medical research, and the tower of babel. N Engl J Med. 2008;358(16):1738–40. https://doi.org/10.1056/NEJMsb0800209.
Li X, Cole SR, Westreich D, Brookhart MA. Primary non-adherence and the new-user design. Pharmacoepidemiol Drug Saf. 2018;27(4):361–4. https://doi.org/10.1002/pds.4403.
Li X, Stürmer T, Brookhart MA. Evidence of sample use among new users of statins: implications for pharmacoepidemiology. Med Care. 2014;52(9):773–80. https://doi.org/10.1097/MLR.0000000000000174.
Li X, Young JG, Toh S. Estimating effects of dynamic treatment strategies in pharmacoepidemiologic studies with time-varying confounding: a primer. Curr Epidemiol Rep. 2017;4(4):288–97. https://doi.org/10.1007/s40471-017-0124-x.
Lu CY. Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases. Clin Rheumatol. 2009;28(4):371–7. https://doi.org/10.1007/s10067-009-1102-6.
Lu CY, Law MR, Soumerai SB, et al. Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study. Clin Ther. 2011;33(1):135–44. https://doi.org/10.1016/j.clinthera.2011.01.012.
Lu CY, Soumerai SB, Ross-Degnan D, Zhang F, Adams AS. Unintended impacts of a medicaid prior authorization policy on access to medications for bipolar illness. Med Care. 2010;48(1):4–9. https://doi.org/10.1097/MLR.0b013e3181bd4c10.
Lu CY, Srasuebkul P, Drew AK, Ward RL, Pearson S-A. Positive spillover effects of prescribing requirements: increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer. Intern Med J. 2012;42(11):1229–35. https://doi.org/10.1111/j.1445-5994.2011.02604.x.
Lu CY, Williams KM, Day RO. Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme? Intern Med J. 2007a;37(9):601–6. https://doi.org/10.1111/j.1445-5994.2007.01396.x.
Lu CY, Williams KM, Day RO. The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines. Aust New Zealand Health Policy. 2007b;4(1):2. https://doi.org/10.1186/1743-8462-4-2.
Lu CY, Zhang F, Lakoma MD, et al. Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. BMJ. 2014;348:g3596. https://doi.org/10.1136/bmj.g3596.
Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144–53. https://doi.org/10.1093/oxfordjournals.aje.a115853.
Maclure M, Fireman B, Nelson JC, et al. When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol Drug Saf. 2012;21(S1):50–61. https://doi.org/10.1002/pds.2330.
Mamdani M, Sykora K, Li P, et al. Reader’s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ. 2005;330(7497):960–2. https://doi.org/10.1136/bmj.330.7497.960.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48. https://doi.org/10.1093/jnci/22.4.719.
McKnight J, Scott A, Menzies D, Bourbeau J, Blais L, Lemière C. A cohort study showed that health insurance databases were accurate to distinguish chronic obstructive pulmonary disease from asthma and classify disease severity. J Clin Epidemiol. 2005;58(2):206–8. https://doi.org/10.1016/j.jclinepi.2004.08.006.
McWilliams JM, Meara E, Zaslavsky AM, Ayanian JZ. Use of health services by previously uninsured Medicare beneficiaries. N Engl J Med. 2007;357(2):143–53. https://doi.org/10.1056/NEJMsa067712.
Morgenstern H. Ecologic studies in epidemiology: concepts, principles, and methods. Annu Rev Public Health. 1995;16(1):61–81. https://doi.org/10.1146/annurev.pu.16.050195.000425.
Motheral BR, Fairman KA. The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin Ther. 1997;19(2):346–66. https://doi.org/10.1016/S0149-2918(97)80122-1.
National Cancer Institute Division of Cancer Control & Population Sciences. SEER-medicare linked database. https://healthcaredelivery.cancer.gov/seermedicare/. Published 3 Oct 2019. Accessed 15 Oct 2019.
Normand S-LT, Sykora K, Li P, Mamdani M, Rochon PA, Anderson GM. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ. 2005;330(7498):1021–3. https://doi.org/10.1136/bmj.330.7498.1021.
OECD Guidelines for Quality Assurance in Genetic Testing—OECD. http://www.oecd.org/sti/emerging-tech/oecdguidelinesforqualityassuranceingenetictesting.htm. Accessed 16 Oct 2019.
OptumLabs Health Care Collaboration & Innovation. https://www.optumlabs.com/. Accessed 15 Oct 2019.
Paniz VMV, Fassa AG, Maia M de FS, Domingues MR, Bertoldi AD. Measuring access to medicines: a review of quantitative methods used in household surveys. BMC Health Serv Res. 2010;10:146. https://doi.org/10.1186/1472-6963-10-146.
PDUFA VI: Fiscal years 2018–2022. FDA. June 2019. http://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-vi-fiscal-years-2018-2022. Accessed 15 Oct 2019.
Perrio M, Waller PC, Shakir SAW. An analysis of the exclusion criteria used in observational pharmacoepidemiological studies. Pharmacoepidemiol Drug Saf. 2007;16(3):329–36. https://doi.org/10.1002/pds.1262.
Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ. 2016;354:i4515. https://doi.org/10.1136/bmj.i4515.
Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 1999;47(6):749–54. https://doi.org/10.1111/j.1532-5415.1999.tb01603.x.
Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915–20. https://doi.org/10.1093/aje/kwg231.
Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338:1516–20.
Robins J. A new approach to causal inference in mortality studies with a sustained exposure period–application to control of the healthy worker survivor effect. Math Model. 1986;7(9–12):1395–512.
Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56(3):779–88. https://doi.org/10.1111/j.0006-341X.2000.00779.x.
Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. [Editorial]. Epidemiology. 2000;11(5):550–60.
Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79(387):516–24. https://doi.org/10.2307/2288398.
Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291–303. https://doi.org/10.1002/pds.1200.
Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther. 2007;82(2):143–56. https://doi.org/10.1038/sj.clpt.6100249.
Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323–37. https://doi.org/10.1016/j.jclinepi.2004.10.012.
Schneeweiss S, Patrick AR, Stürmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45(10 Suppl):S131–42. https://doi.org/10.1097/MLR.0b013e318070c08e.
Schneeweiss S, Stürmer T, Maclure M. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf. 1997;6(Suppl 3):S51–9. https://doi.org/10.1002/(SICI)1099-1557(199710)6:3+<S51::AID-PDS301>3.0.CO;2-S.
Schuemie MJ, Ryan PB, Man KKC, Wong ICK, Suchard MA, Hripcsak G. A plea to stop using the case-control design in retrospective database studies. Stat Med. 2019;38(22):4199–208. https://doi.org/10.1002/sim.8215.
Sentinel Initiative. https://www.sentinelinitiative.org/. Accessed 16 Oct 2019.
Strom BL, Carson JL, Halpern AC, et al. Using a claims database to investigate drug-induced Stevens-Johnson syndrome. Stat Med. 1991;10(4):565–76. https://doi.org/10.1002/sim.4780100408.
Strom BL, Kimmel SE, Hennessy S. Pharmacoepidemiology. 5th ed. Chichester: John Wiley & Sons Ltd; 2012.
Suissa S. The case-time-control design. Epidemiology. 1995;6(3):248–53. https://doi.org/10.1097/00001648-199505000-00010.
Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med. 2003;168(1):49–53. https://doi.org/10.1164/rccm.200210-1231OC.
Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2008;167(4):492–9. https://doi.org/10.1093/aje/kwm324.
Vaccine Safety Datalink (VSD) | VSD | Monitoring | Ensuring Safety | Vaccine Safety | CDC. https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html. Published 17 June 2019. Accessed 16 Oct 2019.
Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147(8):W-163–94.
Vitry AI, Thai LP, Lu CY. Time and geographical variations in utilization of endocrine therapy for breast cancer in Australia. Intern Med J. 2011;41(2):162–6. https://doi.org/10.1111/j.1445-5994.2010.02304.x.
Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299–309. https://doi.org/10.1046/j.1365-2710.2002.00430.x.
Walker AM. Confounding by indication. Epidemiology. 1996;7(4):335–6.
Wettermark B. The intriguing future of pharmacoepidemiology. Eur J Clin Pharmacol. 2013;69(1):43–51. https://doi.org/10.1007/s00228-013-1496-6.
Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25(10):1768–97. https://doi.org/10.1002/sim.2302.
WHO. How to investigate drug use in health facilities: selected drug use indicators—EDM Research Series No. 007. https://apps.who.int/medicinedocs/en/d/Js2289e/. Published 29 Oct 2018. Accessed 15 Oct 2019.
WHOCC. Definition and general considerations. https://www.whocc.no/ddd/definition_and_general_considera/. Accessed 15 October 2019.
Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol. 2004;57(2):131–41. https://doi.org/10.1016/S0895-4356(03)00246-4.
Acknowledgement
We thank Caitlin Lupton, M.Sc., of Harvard Pilgrim Health Care Institute for research assistance and administrative support.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Li, X., Lu, C.Y. (2020). Pharmacoepidemiological Approaches in Health Care. In: Babar, ZUD. (eds) Pharmacy Practice Research Methods. Springer, Singapore. https://doi.org/10.1007/978-981-15-2993-1_9
Download citation
DOI: https://doi.org/10.1007/978-981-15-2993-1_9
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-2992-4
Online ISBN: 978-981-15-2993-1
eBook Packages: MedicineMedicine (R0)